Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Therapy (Dexamethasone, Rituximab, Cyclosporin, IVIG) for Newly Diagnosed ITP
NCT02834468Phase 3Unknown
- Sponsor
- Shandong University
- Start
- Jun 2016
- Primary completion
- Jul 2018
- Modality
- Monoclonal Antibodies, Recombinant Proteins and Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rituximab, cyclosporine, dexamethasone and intravenous immunoglobulin G in immune thrombocytopenia (ITP), sponsored by Shandong University. Primary endpoints: Complete Response at 3 months, Response at 3 months and 2 more. Status: unknown.
02
Drugs
rituximabcyclosporinedexamethasoneintravenous immunoglobulin G
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT02834468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02834468.